0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > OX40

OX40

OX40 Molecule Information

Name:Tumor necrosis factor receptor superfamily member 4
Target Synonym:CD134;TNF Receptor Superfamily Member 4;OX40;Lymphoid Activation Antigene ACT35;OX40L receptor;TAX transcriptionally-activated glycoprotein 1 receptor;ACT35 antigen;TXGP1L;OX40 Cell Surface Antigen;IMD16;TNFRSF4
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Phase ?

OX40 Protein Product ListCompare or Buy

OX40 Part of Bioactivity data

OX0-H5252-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that recombinant Human OX40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OX0-H5252) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.01 μg/mL (Routinely tested).

OX0-H82F7-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that recombinant Biotinylated Human OX40, Fc,Avitag (Cat. No. OX0-H82F7) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.1 μg/mL (Routinely tested).

TN4-H82E4-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Anti-OX40 MAb (Human IgG1) with an affinity constant of 0.115 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

TN4-H82E4-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human OX40, Avitag,His Tag (Cat. No. TN4-H82E4) on SA Biosensor, can bind Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) with an affinity constant of 0.127 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

OX40 Molecule Synonym Name

TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

OX40 Molecule Background

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

OX40 References

OX40 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
INCAGN-1949 INCAGN-1949 Phase Ⅱ Agenus, Ludwig Institute for Cancer Research, Incyte Urogenital cancer, Renal cell carcinoma, Solid tumours Details
SHR-1806 SHR-1806 IND Filing Shanghai Hengrui, Jiangsu Hengrui Medicine, Suzhou Shengdiya Unspecified Details
YH-002 YH-002 Phase Ⅰ Eucure Biopharma Advanced solid tumors Details
BGB-A445 BGB-A445 Phase Ⅰ BeiGene Solid tumours Details
Efizonerimod alfa MEDI-6383,MEDI6383 Phase Ⅰ MedImmune Solid tumours Details
GSK3174998 GSK-3174998; GSK 3174998; GSK3174998 Phase Ⅱ GlaxoSmithKline Solid tumours, Head and neck cancer Details
FS-120 FS-120 IND Filing F-star Cancer Details
PF-04518600 PF-04518600; PF-8600 Phase Ⅱ Pfizer Renal cell carcinoma, Breast cancer, Solid tumours Details
SL-279252 SL-279252; TAK-252 Phase Ⅰ Shattuck Labs Gastric adenocarcinoma, Non small cell lung cancer (NSCLC), Diffuse large B cell lymphoma, Renal cell carcinoma, Urothelial cancer, Solid tumours, Squamous cell carcinoma of head and neck cancer (SCCHN), Hodgkin lymphoma, Gastroesophageal junction adenocarcinoma, Melanoma Details
INBRX-106 INBRX-106 Phase Ⅰ Inhibrx Solid tumours Details
BMS-986178 BMS-986178 Phase Ⅱ Bristol-Myers Squibb Solid tumours Details
Recombinant human anti-OX40 monoclonal antibody (Livzon Group) Phase Ⅰ Livzon Pharmaceutical Group Cancer Details
MEDI-6469 MEDI-6469 Phase Ⅱ AgonOx, Providence Cancer Center, MedImmune Diffuse large B cell lymphoma, Prostate cancer, Breast cancer, Colorectal cancer, Head and neck cancer, Melanoma Details
Recombinant human anti-OX40 monoclonal antibody (Innovent Biologics) IBI-101,IBI101 Phase Ⅰ Innovent Biologics Cancer Details
KHK-4083 KHK-4083 Phase Ⅱ Kyowa Hakko Kirin Ulcerative colitis Details
ATOR-1015 ATOR-1015; ADC-1015 Phase Ⅰ Alligator Bioscience Solid tumours Details
Tavolimab MEDI-0562,MEDI0562 Phase Ⅱ MedImmune Ovarian cancer Details
GBR-830 GBR-830  Phase Ⅱ Glenmark Pharmaceuticals Atopic dermatitis Details
Vonlerolizumab RO-7021608; MOXR-0916; RG-7888 Phase Ⅱ Genentech Solid tumours Details

This web search service is supported by Google Inc.

totop